News and Press Releases
New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
19 March 2025 -- Dublin, Ireland & New Jersey, US -- Amarin Corporation plc today announced that additional in vitro mechanistic data with eicosapentaenoic acid (EPA) will be presented at the American...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2025
MedExecWomen Hosts 6th Annual Conference to Discuss Future of Medtech Industry
18 March 2025 -- Massachusetts, US -- MedExecWomen, a non-profit organization focused on empowering executive women in medtech to accelerate the positive impact of medical devices, diagnostics, drug delivery, and...
Category: Biotechnology, Drug Delivery, Other, Pharmaceutical
Posted: March 18, 2025
Cherwell supports microbiological environmental monitoring best practices conference
Cleanroom microbiology experts on hand at Pharmig’s specialist conference to discuss assessment of sterility in pharmaceutical manufacturing facilities 6 March 2025 -- Bicester, UK -- Cherwell, cleanroom microbiology solutions expert,...
Category: BioManufacturing, Biotechnology, Other, Pharmaceutical
Posted: March 6, 2025
Launton Business Centre Murdock Rd, Bicester OX26 4XB
ELRIG Announces Drs Jue Wang and Robert Grundy as Keynote Speakers at Research & Innovation 2025
24 January 2025 -- Cambridge, UK -- The European Laboratory Research & Innovation Group (ELRIG), a not-for-profit, volunteer-led organisation for the drug discovery community, today announced the keynote speakers for Research...
Category: Drug Discovery, Other, Pharmaceutical
Posted: January 24, 2025
ELRIG (UK) Ltd. Salisbury House, Station Road, Cambridge, CB1 2LA, UK
PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
VE303 was well tolerated and decreased the odds of rCDI through multiple mechanisms Analyses identified predictors of VE303 colonization and protection from CDI recurrence Topline data for the ongoing Phase...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: January 23, 2025
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients across various lines of treatment LYT-200...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 9, 2025
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting
LYT-200 is generally safe and well-tolerated as a single agent as well as in combination with standard-of-care venetoclax and hypomethylating agents LYT-200 demonstrates clinical benefit as a single agent, with...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: December 9, 2024
From Discovery Park to Merck, Top Industry Players to Showcase at London Biotechnology Show 2025
7 November 2024 -- London, UK -- Back for its second year, the London Biotechnology Show (#LBS25) gathers prominent biotech leaders, policymakers, and industry enthusiasts for an unparalleled showcase. Attendees...
Category: Biotechnology, Other, Pharmaceutical
Posted: November 7, 2024
PTC Therapeutics to Participate at Upcoming Investor Conferences
4 November 2024 -- New Jersey, US -- PTC Therapeutics, Inc today announced that the company will present a company overview at the following conferences: UBS Global Healthcare ConferenceWednesday, Nov....
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: November 4, 2024
PTC Therapeutics Inc. 100 Corporate Court South Plainfield, NJ 07080-2449
Travere Therapeutics to Present at Upcoming Investor Conferences
4 November 2024 -- California, US -- Travere Therapeutics, Inc today announced that company management will present in the following upcoming investor conferences in November: Guggenheim Securities Healthcare Innovation ConferenceMonday, November 11,...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: November 4, 2024
PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
Milestone triggers payments to PureTech totaling $29 million under agreements with Royalty Pharma and PureTech’s Founded Entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb in March 2024, and...
Category: Other, Pharmaceutical
Posted: September 27, 2024
Successful Conclusion of London Biotechnology Show, Leaves Attendees Highly Satisfied
10 May 2024 -- London, UK -- The curtain has closed on the debut London Biotechnology Show 2024, leaving attendees thoroughly impressed by the seamless delivery of promised content and...
Category: Biotechnology
Posted: May 10, 2024
